Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Sho

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
Targeted Oncology|September 2, 2024
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab TreatmentTakuya Sho, Goki Suda, Masatsugu Ohara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 21, 2016
Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infectionJun Ito, Goki Suda, Yoshiya Yamamoto, et al.
Carcinogenesis|September 21, 2017
Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinomaOsamu Maehara, Goki Suda, Mitsuteru Natsuizaka, et al.
Journal of Gastroenterology|November 19, 2020
Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infectionKazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, et al.
Carcinogenesis|May 26, 2020
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signalingTaku Shigesawa, Osamu Maehara, Goki Suda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 20, 2017
Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled studyGoki Suda, Jun Ito, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 7, 2022
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver diseaseAkihisa Nakamura, Koji Yamamoto, Rei Takeda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 12, 2014
Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactionsGoki Suda, Yoshiya Yamamoto, Astushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 25, 2024
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective studyZijian Yang, Goki Suda, Takuya Sho, et al.
Journal of Gastroenterology|January 16, 2016
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis CGoki Suda, Mineo Kudo, Atsushi Nagasaka, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Targeted Oncology|September 2, 2024
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab TreatmentTakuya Sho, Goki Suda, Masatsugu Ohara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 21, 2016
Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infectionJun Ito, Goki Suda, Yoshiya Yamamoto, et al.
Carcinogenesis|September 21, 2017
Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinomaOsamu Maehara, Goki Suda, Mitsuteru Natsuizaka, et al.
Journal of Gastroenterology|November 19, 2020
Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infectionKazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, et al.
Carcinogenesis|May 26, 2020
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signalingTaku Shigesawa, Osamu Maehara, Goki Suda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 20, 2017
Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled studyGoki Suda, Jun Ito, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 7, 2022
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver diseaseAkihisa Nakamura, Koji Yamamoto, Rei Takeda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 12, 2014
Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactionsGoki Suda, Yoshiya Yamamoto, Astushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 25, 2024
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective studyZijian Yang, Goki Suda, Takuya Sho, et al.
Journal of Gastroenterology|January 16, 2016
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis CGoki Suda, Mineo Kudo, Atsushi Nagasaka, et al.
Pageof 12